Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 101,817
  • Shares Outstanding, K 75,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,752 K
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.43
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings $-0.09 on N/A
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.34 +2.24%
on 07/02/24
1.50 -8.67%
on 06/05/24
-0.09 (-6.16%)
since 05/31/24
3-Month
1.34 +2.24%
on 07/02/24
1.75 -21.71%
on 04/04/24
-0.05 (-3.52%)
since 04/02/24
52-Week
1.20 +14.17%
on 02/07/24
4.45 -69.21%
on 07/11/23
-2.12 (-60.74%)
since 06/30/23

Most Recent Stories

More News
Cancer Rates Surge: Key Biotech Stocks Leading the Charge in Oncology Drug Development

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
GSK : 38.21 (-0.44%)
GH : 28.87 (+2.16%)
EXEL : 22.15 (-0.45%)
GILD : 68.40 (-0.35%)
Stocks in play: Oncolytics Biotech® Inc.

Announced that the Company received productive feedback from its Type C meeting with the U.S. Food and ...

ONC.TO : 1.37 (+1.48%)
Stocks in play: Oncolytics Biotech Inc

Today announced the Company received productive feedback from its Type C meeting with the U.S. Food ...

ONC.TO : 1.37 (+1.48%)
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, today announced...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
MBIO : 0.5590 (+15.40%)
LEGN : 44.74 (-2.78%)
JNJ : 146.03 (-0.28%)
NRIX : 18.93 (-9.47%)
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
MBIO : 0.5590 (+15.40%)
LEGN : 44.74 (-2.78%)
JNJ : 146.03 (-0.28%)
NRIX : 18.93 (-9.47%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
GOVX : 3.31 (+0.91%)
GSK : 38.21 (-0.44%)
AZN : 76.99 (-1.22%)
MRK : 127.72 (-0.14%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

ONCY : 0.9900 (-0.52%)
ONC.TO : 1.37 (+1.48%)
GOVX : 3.31 (+0.91%)
GSK : 38.21 (-0.44%)
AZN : 76.99 (-1.22%)
MRK : 127.72 (-0.14%)
Stocks in play: Oncolytics Biotech Inc

Announced the dosing of the first patient in the new GOBLET study cohort evaluating pelareorep and modified ...

ONC.TO : 1.37 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the...

See More

Key Turning Points

3rd Resistance Point 1.46
2nd Resistance Point 1.43
1st Resistance Point 1.40
Last Price 1.37
1st Support Level 1.34
2nd Support Level 1.31
3rd Support Level 1.28

See More

52-Week High 4.45
Fibonacci 61.8% 3.21
Fibonacci 50% 2.82
Fibonacci 38.2% 2.44
Last Price 1.37
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar